Amica Mutual Insurance Co. Reduces Position in Pfizer (PFE)

Amica Mutual Insurance Co. decreased its stake in Pfizer (NYSE:PFE) by 27.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 242,055 shares of the biopharmaceutical company’s stock after selling 89,389 shares during the period. Pfizer comprises about 0.9% of Amica Mutual Insurance Co.’s holdings, making the stock its 21st largest holding. Amica Mutual Insurance Co.’s holdings in Pfizer were worth $8,767,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently modified their holdings of the company. BlackRock Inc. raised its stake in shares of Pfizer by 2.8% during the fourth quarter. BlackRock Inc. now owns 452,745,609 shares of the biopharmaceutical company’s stock valued at $16,398,445,000 after acquiring an additional 12,183,218 shares during the last quarter. Bank of New York Mellon Corp raised its stake in shares of Pfizer by 11.9% during the fourth quarter. Bank of New York Mellon Corp now owns 70,738,885 shares of the biopharmaceutical company’s stock valued at $2,562,162,000 after acquiring an additional 7,534,957 shares during the last quarter. Ameriprise Financial Inc. raised its stake in shares of Pfizer by 4.4% during the third quarter. Ameriprise Financial Inc. now owns 59,844,024 shares of the biopharmaceutical company’s stock valued at $2,136,189,000 after acquiring an additional 2,502,659 shares during the last quarter. Fisher Asset Management LLC raised its stake in shares of Pfizer by 3.6% during the fourth quarter. Fisher Asset Management LLC now owns 36,372,349 shares of the biopharmaceutical company’s stock valued at $1,317,407,000 after acquiring an additional 1,251,550 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. raised its stake in shares of Pfizer by 2.3% during the fourth quarter. Schwab Charles Investment Management Inc. now owns 34,547,216 shares of the biopharmaceutical company’s stock valued at $1,251,306,000 after acquiring an additional 790,097 shares during the last quarter. 71.65% of the stock is owned by institutional investors and hedge funds.

NYSE:PFE opened at $35.71 on Friday. The company has a quick ratio of 0.98, a current ratio of 1.27 and a debt-to-equity ratio of 0.45. The firm has a market capitalization of $212.46 billion, a price-to-earnings ratio of 13.48, a P/E/G ratio of 1.77 and a beta of 0.89. Pfizer has a 12 month low of $35.64 and a 12 month high of $35.80.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, May 1st. The biopharmaceutical company reported $0.77 EPS for the quarter, topping analysts’ consensus estimates of $0.74 by $0.03. The business had revenue of $12.91 billion during the quarter, compared to analysts’ expectations of $13.14 billion. Pfizer had a net margin of 41.29% and a return on equity of 25.29%. The business’s quarterly revenue was up 1.0% on a year-over-year basis. During the same period last year, the company posted $0.69 earnings per share. research analysts anticipate that Pfizer will post 2.95 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Friday, June 1st. Shareholders of record on Friday, May 11th will be issued a $0.34 dividend. This represents a $1.36 dividend on an annualized basis and a yield of 3.81%. The ex-dividend date is Thursday, May 10th. Pfizer’s payout ratio is 51.32%.

PFE has been the subject of several analyst reports. Sanford C. Bernstein set a $43.00 price target on shares of Pfizer and gave the company a “buy” rating in a research note on Tuesday, January 30th. JPMorgan Chase reaffirmed a “buy” rating on shares of Pfizer in a research note on Tuesday, January 30th. Zacks Investment Research downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Monday, January 22nd. BMO Capital Markets set a $43.00 price target on shares of Pfizer and gave the company a “buy” rating in a research note on Thursday, February 15th. Finally, SunTrust Banks reaffirmed a “hold” rating and set a $40.00 price target (up previously from $33.00) on shares of Pfizer in a research note on Monday, January 29th. Three equities research analysts have rated the stock with a sell rating, twelve have given a hold rating and nine have given a buy rating to the company. The company has an average rating of “Hold” and an average target price of $40.08.

In other Pfizer news, Director W Don Cornwell sold 1,758 shares of the firm’s stock in a transaction on Tuesday, February 27th. The shares were sold at an average price of $36.79, for a total value of $64,676.82. Following the completion of the sale, the director now directly owns 1,000 shares in the company, valued at $36,790. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Kirsten Lund-Jurgensen sold 9,510 shares of the firm’s stock in a transaction on Monday, February 26th. The stock was sold at an average price of $37.19, for a total transaction of $353,676.90. Following the completion of the sale, the insider now owns 36,959 shares of the company’s stock, valued at $1,374,505.21. The disclosure for this sale can be found here. Insiders sold 380,349 shares of company stock valued at $13,829,340 over the last 90 days. Corporate insiders own 0.06% of the company’s stock.

About Pfizer

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.



Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit